Patents by Inventor Tomohiro Okuda

Tomohiro Okuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11660287
    Abstract: An object of the present invention is to provide an excellent drug for preventing or treating spinocerebellar ataxia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, especially cerebellar atrophy, and is useful as an agent for preventing or treating spinocerebellar ataxia. Cerebellar atrophy observed in spinocerebellar ataxia can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 30, 2023
    Assignee: FUJIFILM Toyama Chemical Co., Ltd.
    Inventors: Hiroshi Kobayashi, Yoshihiko Matsumoto, Tomohiro Okuda
  • Patent number: 11344530
    Abstract: An object of the present invention is to provide an excellent drug for preventing or treating spinocerebellar ataxia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, especially cerebellar atrophy, and is useful as an agent for preventing or treating spinocerebellar ataxia. Cerebellar atrophy observed in spinocerebellar ataxia can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 31, 2022
    Assignee: FUJIFILM Toyama Chemical Co., Ltd.
    Inventors: Hiroshi Kobayashi, Yoshihiko Matsumoto, Tomohiro Okuda
  • Publication number: 20200085787
    Abstract: An object of the present invention is to provide an excellent drug for preventing or treating spinocerebellar ataxia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, especially cerebellar atrophy, and is useful as an agent for preventing or treating spinocerebellar ataxia. Cerebellar atrophy observed in spinocerebellar ataxia can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
    Type: Application
    Filed: June 1, 2018
    Publication date: March 19, 2020
    Applicant: FUJIFILM Toyama Chemical Co., Ltd.
    Inventors: Hiroshi KOBAYASHI, Yoshihiko MATSUMOTO, Tomohiro OKUDA
  • Patent number: 10471044
    Abstract: Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1] [wherein: R1 and R2 are the same or different and represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, etc.; R3 represents an optionally protected hydroxyl group, etc.; and m and n are the same or different and represent an integer of 1 to 6] or a salt thereof. The medicinal composition according to the present invention is useful as a post nerve injury rehabilitation effect-enhancing agent.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: November 12, 2019
    Assignee: FUJIFILM Toyama Chemical Co., Ltd.
    Inventors: Takuya Takahashi, Tomohiro Okuda
  • Publication number: 20180289668
    Abstract: Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1] [wherein: R1 and R2 are the same or different and represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, etc.; R3 represents an optionally protected hydroxyl group, etc.; and m and n are the same or different and represent an integer of 1 to 6] or a salt thereof. The medicinal composition according to the present invention is useful as a post nerve injury rehabilitation effect-enhancing agent.
    Type: Application
    Filed: June 12, 2018
    Publication date: October 11, 2018
    Applicant: TOYAMA CHEMICAL CO., LTD.
    Inventors: Takuya Takahashi, Tomohiro Okuda
  • Patent number: 10039744
    Abstract: Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1] [wherein: R1 and R2 are the same or different and represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, etc.; R3 represents an optionally protected hydroxyl group, etc.; and m and n are the same or different and represent an integer of 1 to 6] or a salt thereof. The medicinal composition according to the present invention is useful as a post nerve injury rehabilitation effect-enhancing agent.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: August 7, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventors: Takuya Takahashi, Tomohiro Okuda
  • Publication number: 20170165227
    Abstract: Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1] [wherein: R1 and R2 are the same or different and represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, etc.; R3 represents an optionally protected hydroxyl group, etc.; and m and n are the same or different and represent an integer of 1 to 6] or a salt thereof. The medicinal composition according to the present invention is useful as a post nerve injury rehabilitation effect-enhancing agent.
    Type: Application
    Filed: January 30, 2015
    Publication date: June 15, 2017
    Applicant: TOYAMA CHEMICAL CO., LTD.
    Inventors: Takuya TAKAHASHI, Tomohiro OKUDA
  • Publication number: 20160323984
    Abstract: A lighting apparatus of a discharge lamp is provided with a power supply section which supplies AC current to the discharge lamp, a power control section which outputs a signal concerning a control power value to the power supply section, and a pulse generating section which outputs a pulse wave to the power supply section. The power control section carries out a control of differentiating the control power value at a first period and the control power value at a second period, in a direction that a difference is reduced between average light intensities or average powers of the discharge lamp at the first period and the second period, in comparison with a case where the control power value is identical at the first period and the second period.
    Type: Application
    Filed: September 19, 2014
    Publication date: November 3, 2016
    Applicant: USHIO DENKI KABUSHIKI KAISHA
    Inventors: Tomohiro OKUDA, Minoru FUKUDA
  • Patent number: 8119625
    Abstract: Disclosed is an agent comprising a benzothiophene alkyl ether derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent at least one group selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an alkenyl group, an alkenyloxy group, an amino group, an alkylsulfonyl group, an arylsulfonyl group, a carbamoyl group, a heterocyclic group, an amino group, a hydroxyl group, a carboxyl group, a nitro group, an oxo group and the like; R3 represents an alkylamino group which may be substituted or an amino or hydroxyl group which may be protected; and m and n independently represent an integer ranging from 1 to 6. The agent is useful as a neurogenesis inducer or a therapeutic agent for neuropathy.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: February 21, 2012
    Assignee: Toyama Chemical Co., Ltd.
    Inventors: Noboru Iwakami, Shigeki Marubuchi, Tomohiro Okuda
  • Publication number: 20090209512
    Abstract: Disclosed is an agent comprising a benzothiophene alkyl ether derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent at least one group selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an alkenyl group, an alkenyloxy group, an amino group, an alkylsulfonyl group, an arylsulfonyl group, a carbamoyl group, a heterocyclic group, an amino group, a hydroxyl group, a carboxyl group, a nitro group, an oxo group and the like; R3 represents an alkylamino group which may be substituted or an amino or hydroxyl group which may be protected; and m and n independently represent an integer ranging from 1 to 6. The agent is useful as a neurogenesis inducer or a therapeutic agent for neuropathy.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 20, 2009
    Applicant: Toyama Chemical Co., Ltd.
    Inventors: Noboru IWAKAMI, Shigeki MARUBUCHI, Tomohiro OKUDA
  • Publication number: 20090093453
    Abstract: Disclosed is an agent comprising a benzothiophene alkyl ether derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent at least one group selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an alkenyl group, an alkenyloxy group, an amino group, an alkylsulfonyl group, an arylsulfonyl group, a carbamoyl group, a heterocyclic group, an amino group, a hydroxyl group, a carboxyl group, a nitro group, an oxo group and the like; R3 represents an alkylamino group which may be substituted or an amino or hydroxyl group which may be protected; and m and n independently represent an integer ranging from 1 to 6. The agent is useful as a neurogenesis inducer or a therapeutic agent for neuropathy.
    Type: Application
    Filed: April 24, 2007
    Publication date: April 9, 2009
    Applicant: Toyama Chemical Co., Ltd
    Inventors: Noboru Iwakami, Shigeki Marubuchi, Tomohiro Okuda